Tag
Dr. Lal PathLabs Limited
6 articles
Dr. Lal PathLabs demonstrated robust early momentum for fiscal year 2027, reporting a 19% year-over-year revenue increase to ₹798 crore in the first quarter, alongside a 27.2% rise in profit after tax. This marks the company's strongest quarterly revenue growth in four years, fueled by increased patient and sample volumes and improved operational efficiencies that expanded EBITDA margins to 31.0%. Strategic initiatives, including a rural outreach program and the launch of innovative diagnostic tests, are contributing to this growth, while the company also approved acquisitions of Sunshine Healthcare in Ghana and Neuome Technologies, signaling an expansion of its geographic reach and technological capabilities. Investors should monitor the integration of these acquisitions and the sustainability of the company’s margin expansion.
Dr Lal PathLabs Independent Director Tenure Completion
Mr. Gurinder Singh Kalra ceased as Independent Director of Dr. Lal PathLabs Ltd upon completion of his tenure on July 26, 2026.
The cessation was formally intimated to NSE and BSE under SEBI Listing R
Dr Lal PathLabs 32nd AGM Approves All Resolutions
Dr Lal PathLabs held its 32nd Annual General Meeting virtually on July 25, 2026, to vote on ten resolutions.
Shareholders approved a final dividend of ₹4 per share and the re-appointment of key direct
Dr. Lal PathLabs 32nd AGM Approves ₹4 Dividend
Dr. Lal PathLabs held its 32nd Annual General Meeting on July 25, 2026, concluding at 11:03 AM IST.
Shareholders approved a final dividend of ₹4 per share for FY ended March 31, 2026, via ordinary res
Dr. Lal PathLabs Q1 FY27 Earnings Call Recording
Dr. Lal PathLabs disclosed availability of its Q1 FY27 earnings call audio recording for investors and analysts.
The disclosure is a regulatory filing made to NSE and BSE pursuant to SEBI LODR Regulat
Dr Lal PathLabs Q1 FY27 Revenue Up 19% YoY
Dr Lal PathLabs reported Q1 FY27 revenue of ₹798 crore, up 19.1% YoY, with PAT of ₹170 crore growing 27.2%.
The company achieved its highest quarterly revenue growth in 4 years, driven by 10.7% sample
Dr Lal PathLabs Q1 Net Profit Rises 28% to ₹1.7B
Approved unaudited standalone and consolidated financial results for Q1 FY27, showing revenue growth of 19% YoY to ₹7.98B.
Declared interim dividend of ₹5 per share (50% on face value ₹10) with record